The CAR-T Cell Therapy Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize on these opportunities. Overall, the CAR-T Cell Therapy market report is an essential resource for market participants who are looking to gain a comprehensive understanding of the market and identify opportunities for growth.
Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: https://shorturl.at/GigkZ
The global CAR-T cell therapy market reached US$ 3.71 billion in 2023 and is expected to reach US$ 33.75 billion by 2031, growing at a CAGR of 32.0% during the forecast period 2024-2031.
CAR-T Cell Therapy: Chimeric Antigen Receptor T-cell (CAR-T) therapy is an advanced form of immunotherapy that involves modifying a patient's own T cells to better recognize and attack cancer cells. In this process, T cells are extracted from the patient's blood, engineered in a laboratory to express a receptor specific to cancer cells, and then reintroduced into the patient's body. CAR-T cell therapy has shown significant promise in treating certain types of blood cancers, such as leukemia and lymphoma, by harnessing the body's immune system to fight cancer more effectively.
Competitive Landscape
The section also contains information related to the new product launches, mergers, acquisitions, collaborations, etc., to give a clear understanding about the competitive landscape prevailing in the global market. With an emphasis on strategies there have been several primary developments done by major companies such as:
Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb Company, Johnson & Johnson, Autolus Therapeutics, Pfizer Inc., BioNTech SE., Merck KGaA, Allogene Therapeutics, Atara Biotherapeutics, Inc
Key Developments:
In May 2024, Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have undergone at least two prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor. This FDA approval makes Breyanzi the CAR-T cell therapy approved for the broadest range of B-cell malignancies, now covering four distinct subtypes of non-Hodgkin lymphoma.
Market Segments
The detailed segmentation offered in the report will help customers get a clear idea about the market segments and the factors that will drive segmental growth. The CAR-T Cell Therapy market has been segmented :
By Therapy Type: Autologous CAR-T Cell Therapy, Allogeneic CAR-T Cell Therapy
By Drug Type: Abecma, Breyanzi, Carvykti, Tecartus, Kymriah, Yescarta
By Target Antigen: CD19, BCMA (B-cell maturation antigen), CD20, CD22, CD30, CD33, GD2, HER2, Others
By Application: Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma, Others
Research Process
Both primary and secondary data sources have been used in the global CAR-T Cell Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Regional Analysis for CAR-T Cell Therapy Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
**The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted**
This Report Covers:
✔ Go-to-market Strategy.
✔ Neutral perspective on the market performance.
✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
✔Customized regional/country reports as per request and country level analysis.
✔ Potential & niche segments and regions exhibiting promising growth covered.
✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Chapter Outline
⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, CAR-T Cell Therapy market segments, study objectives, and years considered.
⏩ Market Landscape: The competition in the Global CAR-T Cell Therapy Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.
⏩ Companies Profiles: The global CAR-T Cell Therapy market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.
⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.
⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the CAR-T Cell Therapy Market.
⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.
⏩ Research Findings: This section of the report showcases the findings and analysis of the report.
⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.
Frequently asked questions:
➠ What is the global sales value, production value, consumption value, import and export of CAR-T Cell Therapy market?
➠ Who are the global key manufacturers of the CAR-T Cell Therapy Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?
➠ What are the CAR-T Cell Therapy market opportunities and threats faced by the vendors in the global CAR-T Cell Therapy Industry?
➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?
➠ What focused approach and constraints are holding the CAR-T Cell Therapy market?
➠ What are the different sales, marketing, and distribution channels in the global industry?
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
